PRG-1801
Phase 1Biologic
PRG-1801 is one of 77 biologic programs targeting Immune Thrombocytopenia. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
56 competitors in Immune Thrombocytopenia
#DrugCompanyPhaseTrials
1Promacta
GSKApproved
Rituxan
RocheApproved
Decadron
AAspen Global Incorporated
Approved
Oncovin
Eli LillyApproved
Plaquenil
Jazz PharmaceuticalsApproved
Rayos
RRoxane Laboratories
Approved
Imuran
LLegacy Health System
Approved
Doptelet
AAkarx
Phase 3
Vyvgart
ArgenxPhase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRG-1801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- TTongji Hospital